吉非替尼靶向药物治疗对肺癌患者生存率及肿瘤标志物的影响

Effects of gefitinib-targeted drug therapy on survival rate and tumor markers in patients with lung cancer

目的探讨吉非替尼靶向药物治疗对肺癌患者生存率及肿瘤标志物的影响。方法选取2016年10月至2018年10月间山东省立第三医院收治的50例肺癌患者,根据治疗方案不同进行分组,采用吉非替尼治疗的25例患者纳入对照组,采用培美曲塞治疗的25例患者纳入研究组。比较两组患者1年生存率、不良反应和细胞因子集落刺激因子(CSF)、白介素-2(IL-2)及肿瘤坏死因子(TNF)水平。结果研究组患者1年生存率和2年生存率分别为92.0%和76.0%,均高于对照组的80.0%和60.0%,差异均有统计学意义(均P <0.05)。研究组患者不良反应发生率为16.0%,低于对照组患者的52.0%,差异有统计学意义(P <0.05)。治疗前,两组患者的CSF、IL-2及TNF水平比较,差异无统计学意义(P> 0.05)。治疗后,研究组患者CSF和IL-2水平均高于对照组,TNF水平低于对照组,差异均有统计学意义(均P <0.05)。结论肺癌患者使用吉非替尼靶向药物治疗,可提高1年及2年生存率,提高CSF和IL-2水平,降低TNF水平。

Objective To investigate the effects of gefitinib-targeted drug therapy on survival rate and tumor markers including cytokine colony stimulating factor( CSF),interleukin-2( IL-2) and tumor necrosis factor( TNF) in patients with lung cancer. Methods Fifty patients with lung cancer admitted to Shandong Provincial Third Hospital from October 2016 to October 2018 were selected and divided into two groups based on different treatment regimens they received. Twenty-five patients receiving gefitinib were included in a control group and 25 patients receiving pemetrexed were included in a study group. One-year survival rate,adverse reactions and levels of cytokines CSF,IL-2 and TNF were compared between the two groups. Results The 1-year and 2-year survival rate was 92. 0% and 76. 0%,respectively in the study group which was higher than 80. 0% and 60. 0%,respectively of the control group( all P < 0. 05). The incidence of adverse reactions was 16. 0% in the study group which was lower than 52. 0% of the control group( P < 0. 05). After the treatment,CSF and IL-2 levels were significantly higher in the study group than those in the control group and TNF level was significantly lower in the study group than in the control group( all P < 0. 05). Conclusion During the treatment of lung cancer,the use of gefitinib-targeted drugs can significantly improve the 1-year and 2-year survival rate,improve the CSF level and IL-2 level,and reduce the TNF level.